Financials data is unavailable for this security.
View more
Year on year Pfizer Inc 's revenues fell -41.70% from 100.33bn to 58.50bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 31.37bn to 2.12bn, a -93.25% decrease.
Gross margin | 71.29% |
---|---|
Net profit margin | -4.61% |
Operating margin | -8.34% |
Return on assets | -1.17% |
---|---|
Return on equity | -2.78% |
Return on investment | -1.43% |
More ▼
Cash flow in USDView more
In 2023, Pfizer Inc increased its cash reserves by 523.29%, or 2.45bn. Cash Flow from Financing totalled 26.07bn or 44.56% of revenues. In addition the company generated 8.70bn in cash from operations while cash used for investing totalled 32.28bn.
Cash flow per share | 0.7289 |
---|---|
Price/Cash flow per share | 40.78 |
Book value per share | 15.48 |
---|---|
Tangible book value per share | -7.41 |
More ▼
Balance sheet in USDView more
Current ratio | 0.8632 |
---|---|
Quick ratio | 0.602 |
Total debt/total equity | 0.7919 |
---|---|
Total debt/total capital | 0.4412 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 3.85% |
---|---|
Div growth rate (5 year) | 3.82% |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -7.10 |
---|---|
EPS (TTM) vs TTM 1 year ago | -112.37 |
More ▼